Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jean-Simon Diallo

Showing results (51-60 of 92) with videos related to

Pageof 10
Sort By:
Communications Biology|May 24, 2020
The strategic combination of trastuzumab emtansine with oncolytic rhabdoviruses leads to therapeutic synergyRozanne Arulanandam, Zaid Taha, Vanessa Garcia, et al.
Frontiers in Immunology|May 8, 2023
Syngeneic mouse model of human HER2+ metastatic breast cancer for the evaluation of trastuzumab emtansine combined with oncolytic rhabdovirusZaid Taha, Mathieu J F Crupi, Nouf Alluqmani, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 18, 2010
Synergistic interaction between oncolytic viruses augments tumor killingFabrice Le Boeuf, Jean-Simon Diallo, J Andrea McCart, et al.
Nature Communications|June 15, 2013
Model-based rational design of an oncolytic virus with improved therapeutic potentialFabrice Le Bœuf, Cory Batenchuk, Markus Vähä-Koskela, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|September 28, 2023
Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, sensitizes cancer cells to VSVΔ51 oncolytic virotherapyBoaz Wong, Anabel Bergeron, Glib Maznyi, et al.
Scientific Reports|February 28, 2023
Safety and efficacy of autologous cell vaccines in solid tumors: a systematic review and meta-analysis of randomized control trialsDonald J Bastin, Joshua Montroy, Michael A Kennedy, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|July 21, 2011
A mechanistic proof-of-concept clinical trial with JX-594, a targeted multi-mechanistic oncolytic poxvirus, in patients with metastatic melanomaTae-Ho Hwang, Anne Moon, James Burke, et al.
Molecular Therapy Oncolytics|April 28, 2016
Oncolytic vesicular stomatitis virus expressing interferon-γ has enhanced therapeutic activityMarie-Claude Bourgeois-Daigneault, Dominic Guy Roy, Theresa Falls, et al.
Plos One|February 2, 2011
Enhancement of vaccinia virus based oncolysis with histone deacetylase inhibitorsHeather MacTavish, Jean-Simon Diallo, Baocheng Huang, et al.
Journal of Virology|December 11, 2012
Resistance to two heterologous neurotropic oncolytic viruses, Semliki Forest virus and vaccinia virus, in experimental gliomaMarkus J V Vähä-Koskela, Fabrice Le Boeuf, Chantal Lemay, et al.
Pageof 10

Showing results (51-60 of 92) with videos related to

Sort By:
Pageof 10
Communications Biology|May 24, 2020
The strategic combination of trastuzumab emtansine with oncolytic rhabdoviruses leads to therapeutic synergyRozanne Arulanandam, Zaid Taha, Vanessa Garcia, et al.
Frontiers in Immunology|May 8, 2023
Syngeneic mouse model of human HER2+ metastatic breast cancer for the evaluation of trastuzumab emtansine combined with oncolytic rhabdovirusZaid Taha, Mathieu J F Crupi, Nouf Alluqmani, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 18, 2010
Synergistic interaction between oncolytic viruses augments tumor killingFabrice Le Boeuf, Jean-Simon Diallo, J Andrea McCart, et al.
Nature Communications|June 15, 2013
Model-based rational design of an oncolytic virus with improved therapeutic potentialFabrice Le Bœuf, Cory Batenchuk, Markus Vähä-Koskela, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|September 28, 2023
Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, sensitizes cancer cells to VSVΔ51 oncolytic virotherapyBoaz Wong, Anabel Bergeron, Glib Maznyi, et al.
Scientific Reports|February 28, 2023
Safety and efficacy of autologous cell vaccines in solid tumors: a systematic review and meta-analysis of randomized control trialsDonald J Bastin, Joshua Montroy, Michael A Kennedy, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|July 21, 2011
A mechanistic proof-of-concept clinical trial with JX-594, a targeted multi-mechanistic oncolytic poxvirus, in patients with metastatic melanomaTae-Ho Hwang, Anne Moon, James Burke, et al.
Molecular Therapy Oncolytics|April 28, 2016
Oncolytic vesicular stomatitis virus expressing interferon-γ has enhanced therapeutic activityMarie-Claude Bourgeois-Daigneault, Dominic Guy Roy, Theresa Falls, et al.
Plos One|February 2, 2011
Enhancement of vaccinia virus based oncolysis with histone deacetylase inhibitorsHeather MacTavish, Jean-Simon Diallo, Baocheng Huang, et al.
Journal of Virology|December 11, 2012
Resistance to two heterologous neurotropic oncolytic viruses, Semliki Forest virus and vaccinia virus, in experimental gliomaMarkus J V Vähä-Koskela, Fabrice Le Boeuf, Chantal Lemay, et al.
Pageof 10